ํA1LN34 โข BVMF
add
์จ๋ผ์ผ๋ ํ๋ง์ํฐ์ปฌ์ค
์ ์ผ ์ข
๊ฐ
R$90.06
52์ฃผ ๋ณ๋ํญ
R$67.16 - R$132.40
์๊ฐ์ด์ก
446.62์ต USD
ํ๊ท ๊ฑฐ๋๋
114.00
์ฃผ๊ฐ์์ต๋ฅ
-
๋ฐฐ๋น์์ต๋ฅ
-
๋ด์ค
์ฌ๋ฌด
์์ต๊ณ์ฐ์
์์ต
์์ด์ต
| (USD) | 2025๋ 9์info | ์ ๋ ๋๋น ๋ณ๋ |
|---|---|---|
์์ต | 12.49์ต | 149.35% |
์ด์๋น | 6.81์ต | 38.42% |
์์ด์ต | 2.51์ต | 325.05% |
์์ด์ต๋ฅ | 20.10 | 190.26% |
์ฃผ๋น ์์ต | 2.90 | 680.00% |
EBITDA | 3.82์ต | 706.75% |
์ ํจ ์ธ์จ | -5.07% | โ |
๋์ฐจ๋์กฐํ
์ด์์ฐ
์ด๋ถ์ฑ
| (USD) | 2025๋ 9์info | ์ ๋ ๋๋น ๋ณ๋ |
|---|---|---|
ํ๊ธ ๋ฐ ๋จ๊ธฐ ํฌ์ | 27.25์ต | -2.00% |
์ด์์ฐ | 48.52์ต | 15.38% |
์ด๋ถ์ฑ | 46.18์ต | 10.67% |
์ด์๊ธฐ์๋ณธ | 2.34์ต | โ |
๋ฐํ ์ฃผ์ | 1.32์ต | โ |
์ฃผ๊ฐ์์์ฐ๋น์จ | 50.88 | โ |
์ด์์ฐ์ด์ต๋ฅ | 19.54% | โ |
์๋ณธ์ด์ต๋ฅ | 30.68% | โ |
ํ๊ธ ํ๋ฆ
์ํ๊ธํ๋ฆ
| (USD) | 2025๋ 9์info | ์ ๋ ๋๋น ๋ณ๋ |
|---|---|---|
์์ด์ต | 2.51์ต | 325.05% |
์์
ํ๊ธ ํ๋ฆ | 3.25์ต | 643.84% |
ํฌ์ ํ๊ธ ํ๋ฆ | 5.01์ต | 1,756.55% |
์๊ธ ์กฐ๋ฌ ํ๊ธ ํ๋ฆ | -4.48์ต | -536.33% |
์ํ๊ธํ๋ฆ | 3.77์ต | 187.07% |
์์ฌ ํ๊ธ ํ๋ฆ | 1.08์ต | 13.00% |
์ ๋ณด
Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list. Wikipedia
์ค๋ฆฝ
2002. 6. 14.
์น์ฌ์ดํธ
์ง์ ์
2,230
